To include your compound in the COVID-19 Resource Center, submit it here.

Afinitor everolimus regulatory update

The U.K.'s NICE issued final guidance recommending against Afinitor everolimus from Novartis for second-line treatment of advanced renal cell carcinoma (RCC). The agency said

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE